Müller F B, Ha H R, Hotz H, Schmidlin O, Follath F, Bühler F R
Br J Clin Pharmacol. 1986;21 Suppl 2(Suppl 2):143S-147S. doi: 10.1111/j.1365-2125.1986.tb02863.x.
Pharmacodynamic and therapeutic studies with a new slow release 240 mg verapamil formulation were performed in a total of 73 patients with essential hypertension (WHO I-II, diastolic greater than or equal to 100 mm Hg). Chronic administration of slow release 240 mg verapamil, one or two tablets in the morning, resulted in 24 h plasma concentration profiles with trough levels greater than 40 ng ml-1 in 14 of 16 patients and good 24 h blood pressure control. There was no correlation between plasma verapamil or norverapamil concentration and blood pressure response. Monotherapy with slow release verapamil was well tolerated and resulted in good blood pressure control (less than or equal to 95 mm Hg diastolic) in 46 of the 57 patients. Responses were best in older patients and those with low plasma renin or higher control blood pressure. Slow release 240 mg verapamil given once daily is a simple and effective regimen.
对一种新的240毫克缓释维拉帕米制剂进行了药效学和治疗学研究，共有73例原发性高血压患者（世界卫生组织I-II级，舒张压大于或等于100毫米汞柱）参与。早晨服用一或两片240毫克缓释维拉帕米进行长期给药，16例患者中有14例的24小时血浆浓度曲线谷值水平大于40纳克/毫升，并实现了良好的24小时血压控制。血浆维拉帕米或去甲维拉帕米浓度与血压反应之间无相关性。57例患者中有46例对缓释维拉帕米单药治疗耐受性良好，且血压控制良好（舒张压小于或等于95毫米汞柱）。老年患者以及血浆肾素水平低或初始血压较高的患者反应最佳。每日服用一次240毫克缓释维拉帕米是一种简单有效的治疗方案。
